Desidustat: First Approval

Desidustat (Oxemia (TM)) is an orally bioavailable, small molecule, hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor developed by Zydus Cadila for the treatment of anaemia associated with chronic kidney disease (CKD), COVID-2019 infections and chemotherapy induced anaemia. Desidustat inhibits prolyl hydroxylase domain enzymes, resulting in the stabilisation of hypoxia-inducible factor which stimulates erythropoietin production and erythropoiesis. In March 2022, desidustat received its first approval in India for the treatment of anaemia in adults with CKD who are either on dialysis or not on dialysis. Desidustat is in clinical development in China for the treatment of anaemia in patients with CKD, in Mexico for the management of COVID-2019 infections and in the USA for the treatment of chemotherapy induced anaemia. This article summarizes the milestones in the development of desidustat leading to this first approval for anaemia associated with CKD.

Automated summary

Desidustat, an orally available small molecule inhibitor, is developed for the treatment of anaemia associated with chronic kidney disease, COVID-2019 infections, and chemotherapy-induced anaemia. It stimulates erythropoiesis by inhibiting prolyl hydroxylase enzymes. Desidustat has received its first approval in India and is undergoing clinical development in other countries.